This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Michael A. Polis, MD, MPH; Henry Masur, MD

JAMA. 1995;273(18):1457-1459.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE SURVIVAL of patients infected with the human immunodeficiency virus (HIV) has improved over the past decade due to the use of antiretroviral therapy and better management of acquired immunodeficiency syndrome (AIDS)—related opportunistic infections. Some opportunistic infections are declining in incidence due to the use of effective chemoprophylaxis. From the period 1985 to 1987 to the period 1991 to 1992, for example, the incidence of Pneumocystis carinii pneumonia (PCP) as an AIDS-defining illness in the United States declined from 60.9% to 42.5% (written communication, Jonathan Kaplan, MD, Centers for Disease Control and Prevention, Atlanta, Ga, March 1995). However, as patients live longer with very low CD4 counts, it is not surprising that the incidence of other opportunistic infections has increased. Over the same time intervals, the incidence of cytomegalovirus (CMV) retinitis has increased from 2.8% of AIDS-defining illnesses to 5.9%.¹Pneumocystis carinii prophylaxis has been responsible for much of . . . [Full Text PDF of this Article]

Author Affiliations
From the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (Dr Polis) and the Critical Care Medicine Department, Warren Grant Magnuson Clinical Center (Dr Masur), National Institutes of Health, Bethesda, Md.

Footnotes
Dr Polis has consulted for Astra USA, Inc, Westboro, Mass, a maker of foscarnet, periodically over the last 3 years. Dr Masur has received two honoraria from Astra USA, Inc, in the last year.

Reprint requests to Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bldg 10, Room 11C103, Bethesda, MD 20892-1880 (Dr Polls).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?